Zambon is announcing today the availability and reimbursement on the Italian market of Xadago® (safinamide) as an add-on to levodopa alone or in combination with other Parkinson’
Milan, Italy, February 29, 2016 - Newron Pharmaceuticals S.p.A. (“Newron”), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of
Spain is the third country in which Xadago® is available for the treatment of adult patients with idiopathic Parkinson’s disease (PD)
Milan – February 22, 2016 – Zambon S.p.A.,
Milan, Italy – January 12, 2016 – Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and its partner
Milan, Italy – December 23, 2016 – Newron Pharmaceuticals S.p.A. (“Newron”, SIX: NWRN), a biopharmaceutical company focused on the development of novel therapies for patients with
Financing Supports Clinical Development of Sarizotan for Patients with Rett Syndrome, a Rare Neurodevelopmental Disease
Milan, Italy – November 20, 2015 – Newron Pharmaceuticals S
Milan, November 13, 2015 – Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron
Meiji Seika Pharma Co., Ltd. (Headquarter: Tokyo, Japan, President: Daikichiro Kobayashi, “Meiji”) announces that it has initiated Phase II/III confirmatory and Phase III long-
Milan, Italy, Sept. 30, 2015 – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel central nervous system (CNS) and pain therapies, and
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
